The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2019 | MRD: venetoclax vs. BTK-inhibitors for CLL
Susan O’Brien
• 1 Jun 2019
Susan O’Brien, MD, of the University of California Irvine, Irvine, CA, discusses how MRD impacts the choice of different treatments for chronic lymphocytic leukemia (CLL), specifically mentioning venetoclax and BTK-inhibitors. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
